ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1738

Characterization of T Cell Subsets in the Synovium of Chronic Inflammatory Joint Diseases

Alexandra Khmelevskaya1, Miranda Houtman2, Kristina Buerki3, Chantal Pauli4, Sam Edalat3, Mojca Frank-Bertoncelj3, Oliver Distler5, Adrian Ciurea6, Caroline Ospelt7 and Raphael Micheroli8, 1Center of Experimental Rheumatology, University Hospital of Zurich, Zürich, Switzerland, 2University of Zurich, Schlieren, Switzerland, 3Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Zürich, Switzerland, 4Department of Pathology, University Hospital Zurich, Zürich, Switzerland, 5Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, 6University Hospital Zurich, Zürich, Switzerland, 7Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, 8University Hospital Zurich, Department of Rheumatology, Zürich, Switzerland

Meeting: ACR Convergence 2022

Keywords: autoimmune diseases, Gene Expression, T Cell

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: T Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Rheumatoid arthritis (RA), psoriatic arthritis (PsA), peripheral spondyloarthritis (pSpA), and undifferentiated arthritis (UA) are chronic immune-mediated conditions characterized by joint inflammation. The specific role and differences of synovial T cells in these diseases remain unknown.

Methods: Ultrasound guided synovial biopsies were performed in 10 RA, 4 PsA, 4 pSpA, and 3 UA patients fulfilling the respective classification criteria. Three osteoarthritis (OA) samples were obtained from joint replacement surgery. Synovial pathotype (pauci-immune, diffuse-myeloid and lympho-myeloid), Krenn score, and presence of neutrophils were assessed by histology. We dissociated fresh synovial tissues and targeted the encapsulation of up to 6000 cells. ScRNA-seq libraries were generated according to 10X Genomics workflow (v3.1) and subsequently sequenced on NovaSeq 6000. Cell Ranger and Seurat R packages were used for data analysis. P-values were calculated using Welch t-test with Bonferroni correction. T cells were identified by high CD3D gene expression. Cells with mitochondrial content greater than 10% were excluded. The repertoire of T cell receptors (TCR) was analyzed through V-gene usage.

Results: Unsupervised graph-based clustering identified one CD8 positive cluster and four CD4 positive clusters with respective marker gene in box brackets: effector memory cells re-expressing CD45RA (EMRA) [GZMK],T follicular helper cells (Tfh) [CXCL13], regulatory T cells (Treg) [FOXP3], and resting naive/central memory T cells (naive/CM) [CCR7]. The subset proportions were similar between diseases, with EMRA and Tfh populations being the most frequent, representing together more than 50% of T cells. However, the proportion was strikingly different in OA, with EMRA occupying more than 75% of all T cells. Total numbers of T cells in OA were low, reflecting the degenerative, non-immune mediated nature of the disease.

T cell subset proportions were similar between histological pathotypes across all diseases suggesting a comparable relative increase in all subpopulations in the lympho-myeloid pathotype.

Further clustering of CD4 EMRA cells revealed two subpopulations differing in expression of genes associated with activation (GZMK, GZMA, DUSP2, DUSP4, CCL5). HLA-B*27-positive patients had significantly reduced (mean 31% vs 60%, p-value=0.0001) and patients with histologically present neutrophils significantly higher proportions of activated CD4 EMRA (mean 65% vs 42%, p-value=0.0038). In addition, activated EMRA subpopulation correlated positive with Krenn score (R=0.4, p-value=0.003).

TCR repertoire was polyclonal with high Simpson diversity in all conditions. No bias in V-gene usage between the conditions was observed.

Conclusion: This analysis of T cells in different chronic inflammatory diseases shows an association of activated EMRA T cells with histological presence of neutrophils, HLA-B*27 negativity and Krenn Score. Deeper analyses are required to find disease specific T cell characteristics and to understand whether this T cell activation influences clinical outcomes such as treatment efficacy and overall prognosis.


Disclosures: A. Khmelevskaya, None; M. Houtman, None; K. Buerki, None; C. Pauli, None; S. Edalat, None; M. Frank-Bertoncelj, None; O. Distler, AbbVie/Abbott, Amgen, GlaxoSmithKlein(GSK), Novartis, Roche, UCB, Kymera, Mitsubishi Tanabe, Boehringer Ingelheim, 4P-Pharma, Acceleron, Alcimed, Altavant Sciences, AnaMar, Arxx, AstraZeneca, Blade Therapeutics, Bayer, Corbus Pharmaceuticals, CSL Behring, Galapagos, Glenmark, Horizon, Inventiva, Lupin, Miltenyi Biotec, Merck/MSD, Prometheus Biosciences, Redx Pharma, Roivant, Sanofi, Topadur, Pfizer, Janssen, Medscape, Patent issued “mir-29 for the treatment of systemic sclerosis” (US8247389, EP2331143), FOREUM Foundation, ERS/EULAR Guidelines, EUSTAR, SCQM (Swiss Clinical Quality Management in Rheumatic Diseases), Swiss Academy of Medical Sciences (SAMW), Hartmann Müller Foundation; A. Ciurea, AbbVie, Novartis, Merck/MSD; C. Ospelt, None; R. Micheroli, None.

To cite this abstract in AMA style:

Khmelevskaya A, Houtman M, Buerki K, Pauli C, Edalat S, Frank-Bertoncelj M, Distler O, Ciurea A, Ospelt C, Micheroli R. Characterization of T Cell Subsets in the Synovium of Chronic Inflammatory Joint Diseases [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/characterization-of-t-cell-subsets-in-the-synovium-of-chronic-inflammatory-joint-diseases/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/characterization-of-t-cell-subsets-in-the-synovium-of-chronic-inflammatory-joint-diseases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology